You are viewing a preview of...

Improved T Cell Immunity Against SARS-CoV-2 – An Innovate Vaccine Strategy to Prevent Viral Infections

An alternative vaccine strategy, targeting T cell epitopes of the nucleocapsid(N) protein which have a considerably lower mutation frequency

Background

This COVID-19 related project is a spin-off project related to the ongoing development of novel T cell activating adjuvants for neoepitope cancer vaccines. Current COVID-19 vaccine efforts are mainly targeting the surface exposed Spike (S) protein using mRNA (Pfizer/BioNTech & Moderna) or viral vectors (Astra-Zeneca, Johnson &Johnson & Sputnik). By raising antibodies against theACE2 receptor-binding domain (RBD), viral host cell interaction can be blocked. This approach has been successful during the first global vaccination campaign. However, there is limited data available regarding long-term immunity and vaccine escape from mutant strains at the moment. Therefore, there will most likely be a need for complementary COVID-19 vaccines in the future.

Here researchers propose an alternative vaccine strategy, targeting T cell epitopes

Log in or create a free account to continue reading